According to IMS Health’s 2008 “Global Pharmaceutical Market and Therapy Forecast,” the global pharmaceutical market will grow 5%–6% in 2008 to total $735–$745 billion. This is down from the 6%–7% growth forecasted for 2007. One of the most notable developments in 2008 will be the rise of the so-called “pharmerging” markets: China, Brazil, Mexico, South […]
The US is planning to adapt Japan’s policies concerning Chinese food imports. Japan imports 60% of its food supply, with approximately 15% coming from China. According to the Japanese health ministry, government and private laboratories test samples from about 10% of all incoming food shipments, since a 2002 scare involving pesticides in Chinese-grown spinach. Japan […]
According to Booz Allen Hamilton’s third annual report on the “Global Innovation 1000”—the 1,000 largest corporate R&D spenders—R&D spending increased 10% in 2006 to $447 billion. Booz Allen Hamilton estimates that the Global Innovation 1000 accounted for 84% of total corporate R&D and 52% of all R&D spending last year, which was estimated at $540 […]
In 2006, demand for oil in Asia increased by 336,000 barrels per day (Mbpd). Consumption of oil products in Asia is projected to grow by 2.8% per year between 2007 and 2012, or 4.24 million barrels per day (MMbpd). Between 2007 and 2012, Chinese demand is forecasted to rise 5.2%, or 400–420 Mbpd, a year […]
The landscape of the generics industry is changing due to a number of high-profile mergers. Mylan Laboratories, a generics manufacturer based in Pennsylvania, jumped to third place in sales ranking among generic firms after purchasing a controlling stake in the Indian generic Matrix Laboratories in January and acquiring the generics division of Merck KGaA in […]
Biotech drug sales in the US have increased an average of 20% over the last five years and reached a total of $39.92 billion in 2006. Growth factors, primarily erythropoietins and colony-stimulating factors, represented 35.4% of the market in 2006. Monoclonal antibodies, mostly for oncology, and autoimmune and inflammation disorders, made up 28.5% of the […]
The steel industry has grown strongly over the past five years and is expected to continue its growth, driven primarily by the Chinese market. Although there are some fears that China might become a large-scale importer of steel, these worries are counterbalanced by the belief that China’s steel will feed domestic demand. Another factor behind […]
According to a study by the National Science Foundation (NSF) of R&D spending at universities and colleges, total spending on science and engineering (S&E) R&D increased 4.3% (or 1.2%, adjusted for inflation) to $47.8 billion in fiscal 2006. Federally funded academic R&D spending in S&E increased 2.9% to $30.0 billion. However, this total represents a […]
Chemical industry insiders are concerned that poor market conditions may lead to a premature downturn in the global industry, despite strong growth for the industry in China and India. Deutsche Bank, for example, expects that a worldwide slowdown in the chemical industry will begin in 2009. This downturn is predicted to have a greater effect […]
A study by the Tufts Center for the Study of Drug Development (CSDD) has found that the number of cancer drugs in clinical development has more than doubled between 1990 and 2006. However, only 8% of these drug candidates received marketing approval during the studied period. When broken down by compound type, market approval percentages […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
